Articles tagged with Drug Therapy
A study of people with chronic lymphocytic leukemia (CLL) found that effectiveness and adverse events are top concerns when choosing treatment. Patients are willing to trade off some drug efficacy for reduced risk of serious side effects, but out-of-pocket costs can significantly influence their choices.
A new study found a positive association between allopurol initiation and recurring doctor visits for gout, highlighting the need for regular chronic disease reviews to evaluate patients' preferences and eligibility for treatment. The study suggests that more frequent monitoring could reduce barriers to successfully treating gout.
A national cooperative group trial is making a handful of experts in rare leukemia available around the clock to reduce high mortality rates. The goal is to decrease induction mortality from 30% to 6.7% by providing timely management and care for patients with acute promyelocytic leukemia.
A new approach, pharmacoscopy, has shown promising results in treating relapsed blood cancer. In the first clinical trial, 88.2% of patients achieved partial or complete remission with personalized therapies guided by pharmacoscopy.
A new study suggests that a breakthrough Alzheimer's treatment could leave millions of people without access to care due to the US healthcare system's limited capacity. The study identifies shortcomings in specialist diagnosis, diagnostic scanners, and infusion centers, and recommends measures to prepare for an Alzheimer's therapy.
A new study found that precision medicine for oncology is less precise for people of Latin American, African, and Asian ancestry due to the lack of diverse genetic population data. A computational tool called LumosVar was created to help researchers sort out potentially inaccurate results and improve precision medicine.
A researcher has discovered a protein that drives tumor growth in gallbladder cancer, providing an important prognostic marker for improved patient outcomes. The findings may lead to more effective treatment options and new drug therapies.
Researchers identified NOX4 enzyme as a key mechanism in kidney cancer recurrence, finding it facilitates survival of cancer cells under drug treatment. The study's findings have potential for developing targeted therapies to reverse the mechanism and prevent further disease progression.
A study published in Lancet Oncology identified MAF amplification as a tool to stratify breast cancer patients for zoledronic acid treatment. In MAF-negative patients, the inclusion of zoledronic acid improved outcomes, while non-postmenopausal MAF-positive patients experienced increased adverse outcomes.
A team of researchers is working on a computer software that can deliver better therapies for patients with life-threatening heart failure. The computer model will take MRI or genetic data of a patient and build a multiscale simulation of their heart, leading to more personalized treatment plans.
Scientists from RUDN University have developed a new way to synthesize 1,2,4-oxadiazole derivatives, including the active ingredient of genetic disorder treatment drugs. The new method simplifies production while reducing costs and enabling high-yield synthesis without expensive reagents.
Researchers found that blood pressure medication only restored normal vascular rhythms in larger vessels, leaving smallest ones unaffected. The study suggests that hypertension worsens age-related decline in microvascular function.
A team of leading European clinicians and scientists presents a unique perspective on how to move forward in the development of exon skipping therapies for DMD. The authors discuss the main challenges and opportunities for these therapeutic agents going forward, including biomarkers in AON drug development and regulatory tools in the EU.
Scientists studying cone snail venom aim to develop new medicines by understanding how the poison works. Researchers have discovered that cone snail toxins can overlap between the immune and central nervous systems in humans, potentially leading to breakthroughs in treatments for neurological diseases like Alzheimer's.
Researchers have identified a gene that may provide potential therapy for cerebral cavernous malformations (CCMs), a condition characterized by enlarged and irregular blood vessels in the central nervous system. The study suggests using angiogenesis inhibitors, such as TSP1, to treat or prevent CCMs.
Scientists have identified genetic processes that enable nerve-supporting cells to transform into specialized versions that facilitate nerve regeneration. This knowledge may lead to new drug therapies for peripheral neuropathies, a set of conditions causing numbness, muscle weakness, and sensitivity.
Researchers have created two new imaging agents that can visualize the formation of tumour-associated blood vessels and track tumour growth. These agents could provide personalized treatment options by identifying patients most likely to respond to therapies targeting new blood vessel growth, leading to more effective cancer treatment.
A new study published in Epilepsia found that cooling treatment for newborns who suffer from perinatal asphyxia significantly reduces the number of children developing epilepsy later in childhood. The research also showed improved cognitive performance, life quality, and life expectancy for these patients.
A new iPhone app called MS Mosaic aims to improve multiple sclerosis management by tracking patients' daily and weekly symptoms. The app collects data through various surveys, performance tests, and wearable device integration, providing insights for more tailored treatment.
Researchers used computational drug discovery and in vitro enzyme assays to identify potential therapeutic protein inhibitors for Chagas disease. The study successfully selected four drug-like compounds that interacted with a key amino acid, demonstrating the promise of docking simulation for identifying effective treatments.
A new drug targeting technique has been developed to target specific cells in the body, potentially improving therapies for immune-related diseases. The approach preferentially targets harmful macrophages while leaving healing cells unaffected, offering a promising solution for conditions such as arthritis and inflammatory bowel diseases.
A Mayo Clinic study found that Liraglutide slowed stomach emptying and led to significant weight loss in treated patients. The degree of stomach emptying delay was associated with the degree of weight loss, suggesting a potential biomarker for individualizing obesity treatment.
A 52-gene risk profile predicts individual patient survival for idiopathic pulmonary fibrosis (IPF) patients, improving the accuracy of current clinical tools. The study's findings have important implications for disease management and treatment decisions.
Researchers identified macrophage migration inhibitory factor (MIF) and its related protein D-dopachrome tautomerase as closely related cytokines associated with progressive MS. A genetic test could identify patients at risk of developing the disease, accelerating drug development for precision medicine.
Researchers developed a drug treatment that prevents bladder wall remodeling, significantly improving bladder compliance in dogs with spinal cord injuries. The study found long-term benefits for animals treated with the broad spectrum MMP inhibitor GM6001.
A recent study published in the BMJ Journal of Sexually Transmitted Infections warns of the rapid increase in drug resistance of Mycoplasma genitalium (MG), a common sexually transmitted infection. The study suggests that reducing azithromycin use, currently used to treat MG, is necessary to mitigate this issue.
Research found that long-term heavy alcohol use affects male and female brains differently, with males showing more pronounced changes in electrical activity. The study suggests a possible mechanism for gender differences in alcohol response, highlighting the need for personalized treatment approaches.
The PATHWAY-2 study finds that salt retention is the main cause of drug-resistant hypertension and that older diuretic medications are the most effective treatment. The research discovered that spironolactone and amiloride work equally well in lowering blood pressure, offering new alternatives for patients with resistant hypertension.
A cancer drug called bosutinib showed promise in slowing cyst growth in patients with autosomal dominant polycystic kidney disease (ADPKD). The study found a 66% reduction in kidney enlargement for those receiving bosutinib compared to placebo.
The University of Arizona Center for Integrative Medicine launched an online curriculum to train family medicine residents in integrative medicine. The 200-hour program improved residents' medical knowledge and clinical utility, with a high completion rate despite busy schedules.
Nutlin-3 targets p53-Mdm2 interaction, enhancing cancer cell growth arrest and apoptosis while producing minimal toxicity. Its potential as an alternative NPC therapy is explored in ongoing clinical trials.
A study by UC Berkeley researchers found that reference pricing is effective in reducing patient spending on prescription drugs. The policy promotes the use of cheaper alternatives over brand-name options, resulting in a 7% increase in prescriptions filled for low-price reference drugs and a 14% decrease in average price paid.
Researchers found that hypothermia can limit cell death and dynamin levels in mice with cerebral blockage. This suggests that dynamin may be a potential drug target for stroke-related neuronal cell death.
Researchers at Nemours Biomedical Research and University of Delaware have developed a patent-pending process to bridge the gap between 3D cell cultures and high throughput screening techniques. This allows for greater predictability of drug effectiveness and toxicity, leading to lower attrition rates in new medicine development.
A four-year grant will explore nanoparticle-mediated manipulation of pro- and anti-inflammatory factors to limit intestinal inflammation and promote wound healing in IBD patients.
Research reveals that many patients with chronic kidney disease experience smell loss, which correlates with poorer nutritional status. Treatment with intranasal theophylline has shown promise in improving smell function and reducing markers of malnutrition in a small group of patients.
A new study published in Clinical Infectious Diseases found that molecular tests detecting genetic mutations rendering TB resistant to drugs may be equally reliable as traditional culture-based tests in predicting treatment outcomes. The research, led by Harvard Medical School scientists, used cough secretion samples from 171 patients ...
A study by Cornell University researchers found that prolonged bisphosphonate use can alter the composition of bone, making it more brittle and susceptible to fractures. The study suggests that long-term treatment beyond FDA recommendations may increase the risk of atypical femoral fractures.
Researchers at the University of Liverpool have developed a novel approach to treating chronic myeloid leukemia (CML), which safely increases treatment success and reduces negative side effects. The study, led by Professor Richard Clark, shows that CML patients with stable responses to treatment can reduce their medication dosage befor...
A recent study published in JAMA found that patients taking cortisone for inflammation conditions have a 65% reduced risk of hip fractures when receiving the osteoporosis medication alendronate. The study analyzed over 400,000 elderly patients and found that only one in four patients received this protective treatment.
Electrochemotherapy (ECT) combines electro-poration with chemotherapy to increase drug uptake in tumor cells, enhancing the radiosensitizing effect. The treatment has been shown to be effective in treating progressive skin tumors in the head and neck area, preserving cosmetic appearance and function of surrounding tissues.
Researchers at the University of York and Leeds have made a major discovery in Hepatitis B Virus assembly, paving the way for new drug treatments. The team identified an 'assembly code' in the genetic material that allows the virus to create a protective casing.
A team of international scientists has identified a critical gene-regulating protein, Bdf1, essential for the survival of Candida albicans. Compounds that bind to this target can disrupt fungal growth, opening the way for novel drug treatments. The discovery offers a promising alternative to existing antifungal therapies.
Researchers have developed a new sequential multiple assignment randomized (SMART) trial method to test two hypotheses at once. This approach allows for the simultaneous evaluation of different treatments, potentially leading to more accurate results and increased efficiency in clinical trials.
A clinical trial comparing traditional ferrous sulfate with a new iron polysaccharide complex preparation found that traditional treatment is more effective in treating iron-deficiency anemia in young children. The study, published in JAMA, showed that a low-dose daily treatment can be effective in restoring normal hemoglobin levels wi...
This study evaluated the effects of fluoride bleaching agents on human enamel. It found that fluorine bleaching agents increased the concentration of fluorine, calcium, and phosphorus ions in the enamel without altering its microhardness.
A new study suggests that dronabinol, an old pharmaceutical product, could be a potential treatment for obstructive sleep apnea. Researchers found that the drug reduced the frequency of apneas and hypopneas during sleep, decreased subjective sleepiness, and improved overall treatment satisfaction.
A new study has found that patients undergoing electroconvulsive therapy (ECT) for psychiatric disorders have a positive experience, with 80% viewing the treatment as useful and 70% finding it more efficacious than drug therapy. The study aims to validate ECT as a less frightening option by improving its administration standards.
A new cancer medicine, larotrectinib, has demonstrated compelling evidence for treating a range of advanced cancers. The therapy, which targets TRK fusion proteins, resulted in responses in 76% of patients across 17 different types of cancer. After 12 months of treatment, 79% of responding patients remained progression-free.
Researchers from Novartis and collaborators have discovered a novel drug candidate, KDU731, to combat the protozoan parasite Cryptosporidium, which causes cryptosporidiosis. This breakthrough offers hope for new treatment options against this disease, which currently has no effective treatments or vaccines.
The chartbook highlights the prevalence of multiple chronic conditions among older adults and women, emphasizing treatment challenges for patients with co-occurring health issues. The data also underscores the significant burden of chronic illness on the healthcare system.
Researchers identified a risk locus for urinary incontinence near the endothelin gene, which is involved in bladder contraction. The study suggests that drugs targeting this pathway may help alleviate symptoms, offering new hope for women suffering from stress and isolated urgency incontinence.
Researchers have identified a protein causing liver fibrosis, paving the way for new treatments. The discovery, led by Professor Jacob George and Doctor Mohammed Eslam, reveals that variations in the interferon lambda 3 (INLF3) protein are responsible for tissue damage in the liver.
Researchers analyzed thousands of social media posts to find that IBD patients are more concerned with the risks of biologic medications than their benefits or financial costs. The study suggests that physicians need to do a better job explaining the pros and cons of treatments.
A Phase 3 clinical trial found that adding mepolizumab to standard treatment for eosinophilic granulomatosis with polyangiitis (EGPA) significantly improved remission rates, with 28% of participants achieving remission after one year. The disease was in remission at weeks 36 and 48 in 32% of participants who received mepolizumab.
The Journal of Ocular Pharmacology and Therapeutics presents novel therapeutic approaches for treating uveitis, including cyclosporine, topical ganciclovir, and regulatory T cell therapy. These advances aim to improve treatment outcomes and quality of life for patients with autoimmune uveitis.
The American College of Physicians recommends treating women with osteoporosis with bisphosphonates or denosumab, while men may also benefit from treatment to reduce vertebral fracture risk. The guideline emphasizes the importance of medication adherence and avoids estrogen therapy due to its associated risks.
A comprehensive review of clinical and basic research studies found that antipsychotics improve outcomes for patients with schizophrenia and related disorders. The benefits of these medications outweigh potential side effects, and delaying treatment can lead to poorer long-term outcomes.
The USPSTF concludes that screening for preeclampsia has a substantial net benefit, allowing for early identification and effective treatment to prevent serious complications. Moderate-certainty evidence supports the effectiveness of well-established treatments in reducing maternal and perinatal morbidity and mortality.
Researchers have identified a new approach to protect patients from graft-versus-host disease by activating signal paths in the gut. The key to preventing GVHD is protecting the epithelial cells, which can be achieved by using RIG-I and STING proteins.